Bharat Parenterals Ltd

Bharat Parenterals Ltd has dispatched a letter to shareholders whose email IDs are not registered, providing details to access the Annual Report for FY 2025-26. This communication, in line with SEBI regulations, includes a web-link to the report and the notice for the 33rd Annual General Meeting (AGM). The AGM is scheduled for September 19, 2026, via Video Conferencing. A cut-off date of September 12, 2026, has been set for determining voting rights for the AGM. The company encourages digitization and provides links for updating KYC and nomination details.

Bharat Parenterals Ltd has announced September 12, 2026, as the record date for determining shareholder eligibility to receive dividends for the financial year 2025-26. This decision is subject to approval by the members at the upcoming Annual General Meeting (AGM) scheduled for September 19, 2026. Shareholders whose names are registered in the company's books as beneficial owners by the close of business hours on the record date will be entitled to the dividend payment.

Bharat Parenterals Ltd has filed its Annual Report for the Financial Year 2025-26, as per SEBI regulations. The report includes the notice for the 33rd Annual General Meeting (AGM) scheduled for September 19, 2026, to be held via Video Conferencing. The report details corporate overview, statutory reports, financial statements (standalone and consolidated), and the AGM notice. Key performance indicators highlight over 32 years of industry experience, reach in 40+ countries, 25% solar-powered operations, 3 integrated growth platforms, 48 registrations in FY2025-26, 214 dossiers across markets, and 3 subsidiaries. The report also contains forward-looking statements and information on the company's founding promoter, Mr. Rameshchandra Desai, and a message from the Chairman & Managing Director.

Bharat Parenterals Ltd has issued a notice for its 33rd Annual General Meeting (AGM) to be held on Saturday, September 19, 2026, at 11:00 a.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of audited financial statements for the fiscal year ended March 31, 2026, declaration of a final dividend of ₹1 per share, and the re-appointment of Mr. Hemang Shah as a director and executive director for a five-year term starting July 2, 2026. The notice also details the schedule for remote e-voting, with the cut-off date for e-voting and attending the AGM being September 12, 2026.

Bharat Parenterals Limited has announced that its equity shares have been admitted to dealings on the Capital Market Segment of the National Stock Exchange of India Limited (NSE). This follows permission granted by NSE, effective August 17, 2026. The company's shares will now be traded on NSE under the 'Permitted to Trade' category, in addition to their existing listing on BSE Limited. The NSE circular, dated August 14, 2026, details the admission and trading regulations, including designated security codes and market lot sizes. This dual listing is expected to enhance liquidity and market accessibility for the company's shares.

Bharat Parenterals Limited announced a strategic enhancement to its wholly-owned subsidiary, Varenyam Biolifesciences Private Limited's, upcoming Savli manufacturing facility. The facility's scope has been upgraded to include biologics and biosimilar CDMO capabilities, in addition to its existing oncology-focused operations. The Phase 1 capital expenditure has been revised to ₹300 crore from the previously planned ₹150 crore. This expansion aims to address gaps in the global biologics supply chain and target markets in the United States, European Union, and SRA Rest-of-World. Regulatory approvals from USFDA, EU-GMP, and ANVISA will be pursued, with an expected completion date of Q2 2028. The company believes this move will strengthen long-term capabilities and capitalize on the evolving biologics and biosimilar CDMO opportunity.

Bharat Parenterals Ltd announced the outcome of its Board Meeting held on August 05, 2026. The board approved and took on record the Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report and Management Discussion and Analysis Report. Additionally, the company fixed September 19, 2026, as the date for its 33rd Annual General Meeting (AGM) to be held through Video Conferencing. The re-appointment of Mr. Hemang Shah as an Executive Director for a term of five years was also approved, subject to member approval at the AGM. An appointment of a scrutinizer for the e-voting process at the AGM was also made.

Bharat Parenterals Ltd announced the re-appointment of Mr. Hemang Shah as Executive Director for a term of five years, effective July 2, 2026, until July 1, 2031. This decision was made by the Board of Directors based on recommendations from the Nomination and Remuneration Committee and the Audit Committee. The re-appointment is subject to shareholder approval at the upcoming Annual General Meeting. Mr. Shah has been associated with the company for over two decades and possesses over 30 years of experience. The company confirmed he is not debarred from holding a director's office. Details as per SEBI LODR Regulations are provided in Annexure A.

Bharat Parenterals Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results along with the Limited Review Report and Management Discussion and Analysis Report. The company also fixed the date for its 33rd Annual General Meeting as September 19, 2026, and approved related meeting documents. Additionally, the re-appointment of Mr. Hemang Shah as Executive Director for a five-year term was approved, subject to shareholder approval.

Bharat Parenterals Ltd has announced a Board of Directors meeting scheduled for August 5, 2026. The primary agenda is to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. Concurrently, the company has closed its trading window for designated persons from July 1, 2026, until 48 hours after the results declaration, in compliance with SEBI (Prohibition of Insider Trading) Regulations. The notice is also available on the company's website.